Afficher la notice abrégée

A Nano-Emulsion Platform Functionalized with a Fully Human scFv-Fc Antibody for Atheroma Targeting: Towards a Theranostic Approach to Atherosclerosis

hal.structure.identifierCentre de résonance magnétique des systèmes biologiques [CRMSB]
hal.structure.identifierInstitut de Chimie de la Matière Condensée de Bordeaux [ICMCB]
dc.contributor.authorBONNET, Samuel
hal.structure.identifierAcides Nucléiques : Régulations Naturelle et Artificielle [ARNA]
dc.contributor.authorPRÉVOT, Geoffrey
hal.structure.identifierInstitut de Chimie de la Matière Condensée de Bordeaux [ICMCB]
dc.contributor.authorMORNET, Stéphane
hal.structure.identifierCentre de résonance magnétique des systèmes biologiques [CRMSB]
dc.contributor.authorJACOBIN-VALAT, Marie-Josée
hal.structure.identifierAcides Nucléiques : Régulations Naturelle et Artificielle [ARNA]
dc.contributor.authorMOUSLI, Yannick
hal.structure.identifierCentre de résonance magnétique des systèmes biologiques [CRMSB]
dc.contributor.authorHEMADOU, Audrey
hal.structure.identifierInstitut de Chimie de la Matière Condensée de Bordeaux [ICMCB]
dc.contributor.authorDUTTINE, Mathieu
hal.structure.identifierCentre de résonance magnétique des systèmes biologiques [CRMSB]
dc.contributor.authorTROTIER, Aurélien
hal.structure.identifierCentre de résonance magnétique des systèmes biologiques [CRMSB]
dc.contributor.authorSANCHEZ, Stéphane
hal.structure.identifierBaculovirus et Thérapie
dc.contributor.authorDUONOR-CÉRUTTI, Martine
hal.structure.identifierAcides Nucléiques : Régulations Naturelle et Artificielle [ARNA]
dc.contributor.authorCRAUSTE-MANCIET, Sylvie
hal.structure.identifierCentre de résonance magnétique des systèmes biologiques [CRMSB]
dc.contributor.authorCLOFENT-SANCHEZ, Gisèle
dc.date.issued2021
dc.identifier.issn1661-6596
dc.description.abstractEnAtherosclerosis is at the onset of the cardiovascular diseases that are among the leading causes of death worldwide. Currently, high-risk plaques, also called vulnerable atheromatous plaques, remain often undiagnosed until the occurrence of severe complications, such as stroke or myocardial infarction. Molecular imaging agents that target high-risk atheromatous lesions could greatly improve the diagnosis of atherosclerosis by identifying sites of high disease activity. Moreover, a “theranostic approach” that combines molecular imaging agents (for diagnosis) and therapeutic molecules would be of great value for the local management of atheromatous plaques. The aim of this study was to develop and characterize an innovative theranostic tool for atherosclerosis. We engineered oil-in-water nano-emulsions (NEs) loaded with superparamagnetic iron oxide (SPIO) nanoparticles for magnetic resonance imaging (MRI) purposes. Dynamic MRI showed that NE-SPIO nanoparticles decorated with a polyethylene glycol (PEG) layer reduced their liver uptake and extended their half-life. Next, the NE-SPIO-PEG formulation was functionalized with a fully human scFv-Fc antibody (P3) recognizing galectin 3, an atherosclerosis biomarker. The P3-functionalized formulation targeted atheromatous plaques, as demonstrated in an immunohistochemistry analyses of mouse aorta and human artery sections and in an Apoe−/− mouse model of atherosclerosis. Moreover, the formulation was loaded with SPIO nanoparticles and/or alpha-tocopherol to be used as a theranostic tool for atherosclerosis imaging (SPIO) and for delivery of drugs that reduce oxidation (here, alpha-tocopherol) in atheromatous plaques. This study paves the way to non-invasive targeted imaging of atherosclerosis and synergistic therapeutic applications.
dc.description.sponsorshipTranslational Research and Advanced Imaging Laboratory - ANR-10-LABX-0057
dc.description.sponsorshipOptimization of therapeutic monoclonal antibodies development Better antibodies, better developed AND better used - ANR-10-LABX-0053
dc.language.isoen
dc.publisherMDPI
dc.subject.enAtherosclerosis
dc.subject.enNano-emulsion
dc.subject.enMagnetic resonance imaging
dc.subject.enStealth
dc.subject.enHuman antibody
dc.subject.enAtherosclerosis
dc.title.enA Nano-Emulsion Platform Functionalized with a Fully Human scFv-Fc Antibody for Atheroma Targeting: Towards a Theranostic Approach to Atherosclerosis
dc.typeArticle de revue
dc.identifier.doi10.3390/ijms22105188
dc.subject.halChimie/Chimie thérapeutique
dc.subject.halSciences du Vivant [q-bio]/Ingénierie biomédicale/Imagerie
dc.subject.halChimie/Matériaux
bordeaux.journalInternational Journal of Molecular Sciences
bordeaux.page5188
bordeaux.volume22
bordeaux.issue10
bordeaux.peerReviewedoui
hal.identifierhal-03227812
hal.version1
hal.popularnon
hal.audienceInternationale
hal.origin.linkhttps://hal.archives-ouvertes.fr//hal-03227812v1
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=International%20Journal%20of%20Molecular%20Sciences&rft.date=2021&rft.volume=22&rft.issue=10&rft.spage=5188&rft.epage=5188&rft.eissn=1661-6596&rft.issn=1661-6596&rft.au=BONNET,%20Samuel&PR%C3%89VOT,%20Geoffrey&MORNET,%20St%C3%A9phane&JACOBIN-VALAT,%20Marie-Jos%C3%A9e&MOUSLI,%20Yannick&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée